



Evidence reviews – August 2024

Evidence review

Published: 13 August 2024

www.nice.org.uk

The following documents contain the evidence that was used to develop the 2024 recommendations:

- [Prognostic factors for progression of non-proliferative diabetic retinopathy](#)
- [Different thresholds or criteria for starting treatment for non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, and diabetic macular oedema](#)
- [Effectiveness of intensive treatments to lower blood glucose levels](#)
- [Effectiveness of lipid modification therapies and antihypertensive medicines](#)
- [Effectiveness and acceptability of anti-vascular endothelial growth factor agents and laser photocoagulation \(alone or in combination\) for the treatment of non-proliferative and proliferative diabetic retinopathy](#)
- [Vitrectomy](#)
- [Effectiveness and acceptability of intravitreal steroids, macular laser and anti-vascular endothelial growth factor agents for treating diabetic macular oedema](#)
- [Clinical features for switching or stopping treatment for proliferative diabetic retinopathy or diabetic macular oedema](#)
- [Treatments before, during or after cataract surgery](#)
- [Effectiveness of different monitoring frequencies](#)
- [Diagnostic accuracy of ultrawide-field fundus photography and optical coherence tomography](#)

Other supporting evidence

- [Methods](#)
- [Economic model report](#)